Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mechanical respiratory support in cardiogenic shock: reply

    Research output: Contribution to journalComment/debateResearchpeer-review

  1. Prevalence and incidence of various Cancer subtypes in patients with heart failure vs matched controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Coronary risk of patients with valvular heart disease: prospective validation of CT-Valve Score

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cognitive impairment and psychopathology in out-of-hospital cardiac arrest survivors in Denmark: The REVIVAL cohort study protocol

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Left-sided heart disease and risk of death in patients with end-stage kidney disease receiving haemodialysis: an observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIMS: To determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes.

METHODS AND RESULTS: LIVE was an investigator-initiated, randomised, double-blinded, placebo-controlled multicentre trial. Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45%) were recruited (February 2012 to August 2015). Patients were clinically stable and on optimal heart failure treatment. Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks. The LVEF was similar at baseline in the liraglutide and the placebo group (33.7 ± 7.6% vs. 35.4 ± 9.4%). Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95% confidence interval) was -0.8% (-2.1, 0.5; P = 0.24). Heart rate increased with liraglutide [mean difference: 7 b.p.m. (5, 9), P < 0.0001]. Serious cardiac events were seen in 12 (10%) patients treated with liraglutide compared with 3 (3%) patients in the placebo group (P = 0.04).

CONCLUSION: Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed.

Original languageEnglish
JournalEuropean Journal of Heart Failure
Volume19
Issue number1
Pages (from-to)69-77
ISSN1388-9842
DOIs
Publication statusPublished - 2017

ID: 49154599